UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
X Quarterly report pursuant to Section 13 or 15(d) of the
- -------- Securities Exchange Act of 1934. For the quarterly period
ended March 31, 2000.
Transition report pursuant to Section 13 or 15(d) of the
- -------- Securities Exchange Act of 1934. For the transition period
from _____ to _____.
Commission File Number
0-27410
INCARA PHARMACEUTICALS CORPORATION
----------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 56-1924222
------------------------------ -----------------------
(State or other jurisdiction of incorporation (I.R.S. Employer
or organization) Identification Number)
P.O. Box 14287
3200 East Highway 54
Cape Fear Building, Suite 300
Research Triangle Park, NC 27709
- --------------------------- ----------------------
(Address of Principal Executive Office) (Zip Code)
Registrant's Telephone Number, Including Area Code 919-558-8688
----------------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. YES X NO
-------- --------
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Class Outstanding as of May 9, 2000
------------------ -----------------------------
Common Stock, par value $.001 7,284,261 Shares
INCARA PHARMACEUTICALS CORPORATION
INDEX TO FORM 10-Q
PAGE
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets as of March 31, 2000 (unaudited)
and September 30, 1999 . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . 3
Consolidated Statements of Operations for the Three Months and Six
Months ended March 31, 2000 and 1999 (unaudited) . . . . . . . . . . . . . . . . . . . 4
Consolidated Statements of Cash Flows for the Six Months ended
March 31, 2000 and 1999 (unaudited) . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . 6
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations . . . . . . . . . . . . . . . . . 9
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K . . . . . . . . . . . . . . . . . . . 14
SIGNATURE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share data)
March 31, September 30,
2000 1999
----------------- ------------------
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 10,522 $ 2,407
Marketable securities - 2,553
Accounts receivable 213 282
Prepaids and other current assets 255 237
----------------- ------------------
Total current assets 10,990 5,479
Property and equipment, net 161 2,483
Other assets - 82
----------------- ------------------
$ 11,151 $ 8,044
================= ==================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 450 $ 654
Accrued expenses 1,637 1,933
Current portion of capital lease obligations 9 488
Current portion of notes payable 27 197
----------------- ------------------
Total current liabilities 2,123 3,272
Long-term portion of capital lease obligations 27 399
Long-term portion of notes payable - 582
Stockholders' equity:
Common stock, $.001 par value per share, 40,000,000 shares
authorized, 7,144,261 and 5,226,969 shares issued and
outstanding at March 31, 2000 and September 30, 1999,
respectively 7 5
Additional paid-in capital 88,093 81,772
Restricted stock (320) (744)
Accumulated deficit (78,779) (77,242)
----------------- ------------------
Total stockholders' equity 9,001 3,791
----------------- ------------------
$ 11,151 $ 8,044
================= ==================
The accompanying notes are an integral part of these consolidated financial
statements.
3
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
Three Months Ended Six Months Ended
March 31, March 31,
-------------------------------- --------------------------------
2000 1999 2000 1999
-------------- --------------- -------------- ---------------
Revenue:
Contract and license fee revenue $ - $ 209 $ 100 $ 400
-------------- --------------- -------------- ---------------
Costs and expenses:
Research and development 1,246 5,602 3,625 11,420
Purchased in-process research
and development 6,664 - 6,664 -
General and administrative 690 842 1,252 1,489
-------------- --------------- -------------- ---------------
Total costs and expenses 8,600 6,444 11,541 12,909
-------------- --------------- -------------- ---------------
Loss from operations (8,600) (6,235) (11,441) (12,509)
Gain on sale of division - - 9,751 -
Investment income, net 140 59 153 212
-------------- --------------- -------------- ---------------
Net loss $(8,460) $(6,176) $(1,537) $(12,297)
============== =============== ============== ===============
Net loss per common share:
Basic $ (1.53) $ (0.85) $ (0.29) $ (1.68)
============== =============== ============== ===============
Diluted $ (1.53) $ (0.85) $ (0.29) $ (1.68)
============== =============== ============== ===============
Weighted average common shares
outstanding 5,535 7,306 5,379 7,301
============== =============== ============== ===============
The accompanying notes are an integral part of these consolidated financial
statements.
4
INCARA PHARMACEUTICALS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Six Months Ended
March 31,
---------------------------------
2000 1999
-------------- ---------------
Cash flows from operating activities:
Net loss $(1,537) $(12,297)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 210 390
Purchased in-process research and development 6,664 -
Gain on sale of division (9,751) -
Loss on disposal of property and equipment 35 -
Noncash compensation 363 659
Change in assets and liabilities:
Accounts receivable 69 1,061
Prepaids and other assets (22) (5)
Accounts payable and accrued expenses (1,010) (351)
-------------- ---------------
Net cash used in operating activities (4,979) (10,543)
-------------- ---------------
Cash flows from investing activities:
Proceeds from sale of division 11,000 -
Proceeds from sales and maturities of marketable securities 2,553 7,799
Purchases of marketable securities - (1,044)
Purchases of property and equipment (31) (278)
-------------- ---------------
Net cash provided by investing activities 13,522 6,477
-------------- ---------------
Cash flows from financing activities:
Net proceeds from issuance of stock 52 166
Repurchase of Incara stock (332) -
Advances from former parent, net - 98
Principal payments on notes payable (56) (93)
Principal payments on capital lease obligations (92) (163)
-------------- ---------------
Net cash provided by (used in) financing activities (428) 8
-------------- ---------------
Net increase (decrease) in cash and cash equivalents 8,115 (4,058)
Cash and cash equivalents at beginning of period 2,407 10,647
-------------- ---------------
Cash and cash equivalents at end of period $10,522 $ 6,589
============== ===============
The accompanying notes are integral part of these unaudited consolidated
financial statements.
5
INCARA PHARMACEUTICALS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
A. Basis of Presentation
The "Company" or "Incara" refers collectively to Incara Pharmaceuticals
Corporation and its wholly owned subsidiaries, Aeolus Pharmaceuticals, Inc., a
Delaware corporation ("Aeolus") and Renaissance Cell Technologies, Inc., a
Delaware corporation ("Renaissance").
Incara conducts discovery and development programs in three areas: (1)
inflammatory bowel disease, using an ultra-low molecular weight heparin; (2)
liver disorders, using hepatic precursor cell therapy; and (3) small molecule
antioxidants for disorders such as stroke, asthma and chronic bronchitis.
All significant intercompany activity has been eliminated in the
preparation of the consolidated financial statements. The unaudited consolidated
financial statements have been prepared in accordance with the requirements of
Form 10-Q and Rule 10-01 of Regulation S-X. Some information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to those rules and regulations. In the opinion of management, the
accompanying unaudited consolidated financial statements include all adjustments
(consisting only of normal recurring adjustments) necessary to present fairly
the consolidated financial position, results of operations and cash flows of the
Company. The consolidated balance sheet at September 30, 1999 was derived from
the Company's audited financial statements included in the Company's Annual
Report on Form 10-K. The unaudited consolidated financial statements included
herein should be read in conjunction with the audited consolidated financial
statements and the notes thereto included in the Company's Annual Report on Form
10-K for the fiscal year ended September 30, 1999 and in the Company's other
Securities and Exchange Commission ("SEC") filings. Results for the interim
period are not necessarily indicative of the results for any other interim
period or for the full fiscal year.
B. Recent Accounting Pronouncements
In June 1998, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards No. 133, "Accounting for Derivative
Instruments and Hedging Activities" ("SFAS 133"). SFAS 133 establishes
accounting and reporting standards for derivative instruments, including some
derivative instruments embedded in other contracts (collectively referred to as
derivatives), and for hedging activities. SFAS 133 will be effective for all
fiscal quarters of all fiscal years beginning after June 15, 2000, with earlier
application encouraged. The Company does not currently use derivative
instruments, nor does it intend in the future to use derivative instruments.
Therefore, the Company does not expect that the adoption of SFAS 133 will have
any impact on its financial position or results of operations.
6
In December 1999, the SEC issued Staff Accounting Bulletin No. 101,
"Revenue Recognition in Financial Statements," ("SAB 101"), which provides
guidance on the recognition, presentation, and disclosures of revenue in
financial statements filed with the SEC. SAB 101, as amended by SAB 101A,
outlines the basic criteria that must be met to recognize revenue and provides
guidance for disclosures related to revenue recognition policies. The Company
does not expect SAB 101 to have a significant impact on the Company's revenue
recognition policies.
C. Purchased In-Process Research and Development
The acquisition cost of in-process technology that at the date of
purchase has not achieved technological feasibility and has no alternative
future use is charged to operations in the period such technology is acquired.
Purchased in-process research and development costs for the three months and six
months ended March 31, 2000 relate to the acquisition of the minority interests
of Renaissance and Aeolus (see Note F).
D. Net Loss Per Common Share
The Company computes basic net loss per common share using the weighted
average number of shares of common stock outstanding during the period. The
Company computes diluted net loss per common share using the weighted average
number of shares of common and dilutive potential common shares outstanding
during the period. Potential common shares consist of stock options using the
treasury stock method and are excluded if their effect is antidilutive. For the
three-month and six-month periods ended March 31, 2000 and 1999, the weighted
average shares outstanding used in the calculation of net loss per common share
did not include potential shares outstanding because they had the effect of
reducing net loss per common share.
E. Sale of IRL
On December 29, 1999, the Company sold its anti-infective division,
known as Incara Research Laboratories ("IRL"), to a private pharmaceutical
company for $11,000,000 in cash and the right to receive up to an additional
$4,000,000 if a compound originating from a collaboration between the Company
and Merck & Co., Inc. (the "Merck Collaboration") reaches preclinical and
clinical trial milestones. The transaction involved the sale of assets
associated with Incara's anti-infective division, including rights under the
Merck Collaboration and the assumption of related liabilities by the purchaser.
In December 1999, the Company recognized a gain of $9,751,000 on the sale of
IRL. The Company remains contingently liable through May 2007 on some debt and
lease obligations of approximately $9,000,000 assumed by the purchaser,
including the IRL facility lease in Cranbury, New Jersey.
F. Acquisitions
On March 31, 2000, Incara purchased all of the minority interests of
Renaissance and Aeolus. Prior to the acquisition, Incara owned 78.0% of
Renaissance and 65.8% of Aeolus. Incara issued 1,220,041 shares of its common
stock in exchange for the subsidiaries' minority ownership. The acquisition has
been accounted for using the purchase method of accounting.
7
The total purchase price of $6,664,000 consisted of 1,220,041 shares of
Incara's common stock with a fair value of $5.46 per share, based on the price
of the Company's common stock at the date of acquisition. The total purchase
price was allocated to purchased in-process research and development and
immediately charged to operations because the in-process research purchased was
in preclinical stages and feasibility had not been established at the date of
the acquisition and was deemed to have no alternative future use. Additionally,
Renaissance and Aeolus had no workforce or other tangible fixed assets.
Renaissance and Aeolus had incurred approximately $10,000,000 in
research and development costs prior to the acquisition of the minority
interests by Incara. Incara expects that it will take until at least 2006 and
that Renaissance and Aeolus will spend in excess of an additional $50,000,000 to
complete development of all aspects of the research.
G. Stock Transactions
In May 1998, Incara acquired Transcell Technologies, Inc.
("Transcell"), which became IRL. Incara issued the third and final installment
of the purchase price of 856,861 shares of Incara common stock to the former
stockholders of Transcell on February 8, 2000. The number of shares issued was
calculated using a formula based on the average market price of Incara common
stock prior to the stock issuance date. The issuance of these additional shares
did not impact the Company's fiscal 2000 operating results, because the value of
these shares was included in the determination of the purchase price of
Transcell in fiscal 1998.
On January 18, 2000, the Company's Board of Directors authorized the
repurchase of up to $2,000,000 of Incara's common stock during the following two
months through purchases on the stock market. During that period, the Company
repurchased 104,100 shares of common stock at a cost of $332,000.
8
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations.
Introduction
Unless otherwise noted, the phrase "we" or "our" refers collectively to
Incara Pharmaceuticals Corporation and its wholly owned subsidiaries, Aeolus
Pharmaceuticals, Inc. and Renaissance Cell Technologies, Inc.
This Report contains, in addition to historical information, statements
by us with respect to expectations about its business and future results, which
are "forward-looking" statements under the Private Securities Litigation Reform
Act of 1995. These statements and other statements made elsewhere by us or our
representatives, which are identified or qualified by words such as "likely,"
"will," "suggests," "expects," "might," "believe," "could," "should," "would,"
"anticipates," "targets, " "plans" or similar expressions, are based on a number
of assumptions that are subject to risks and uncertainties. Actual results could
differ materially from those currently anticipated or suggested due to a number
of factors, including those set forth herein, those set forth in our Annual
Report on Form 10-K and in our other SEC filings, and including risks relating
to the early stage of products under development, uncertainties relating to
clinical trials and regulatory reviews, the need for additional funds,
competition and dependence on collaborative partners. All forward-looking
statements are based on information available as of the date hereof, and we do
not assume any obligation to update forward-looking statements.
We conduct discovery and development programs in three areas: (1)
inflammatory bowel disease, using an ultra-low molecular weight heparin known as
OP2000; (2) liver disorders, using hepatic precursor cell therapy; and (3) small
molecule antioxidants for disorders such as stroke, asthma and chronic
bronchitis.
On December 29, 1999, we sold our anti-infective division, known as
Incara Research Laboratories, or IRL, to a private pharmaceutical company for
$11,000,000 in cash and the right to receive future payments totaling up to an
additional $4,000,000 in the event a compound originating from a collaboration
with Merck & Co., Inc. reaches preclinical and clinical trial milestones. The
transaction involved the sale of assets associated with Incara's anti-infective
division, including rights under the collaboration with Merck and the assumption
of related liabilities by the purchaser. We remain contingently liable through
May 2007 on some debt and lease obligations of approximately $9,000,000 assumed
by the purchaser, including the IRL facility lease in Cranbury, New Jersey. We
recognized a gain of $9,751,000 on the sale of IRL, which was recorded as other
income.
On March 31, 2000, Incara acquired all of the minority interests of
Renaissance and Aeolus. Prior to the acquisition, Incara owned 78.0% of
Renaissance and 65.8% of Aeolus. Incara issued 1,220,041 shares of its common
stock for the subsidiaries' minority ownership. The acquisition has been
accounted for using the purchase method of accounting with a total purchase
price of $6,664,000. The total purchase price was allocated to purchased
in-process research and development and immediately charged to operations
because the in-process research purchased was in preclinical stages and
feasibility had not been established at the date of the
9
acquisition and was deemed to have no alternative future use. We estimated at
the acquisition date that Renaissance and Aeolus will spend in excess of an
additional $50,000,000 to complete the research and development and that it
would be at least 2006 before the research and development is completed. The
cost to complete research and development for these programs may be shared with
collaborative partners in the future.
Results of Operations
We incurred net losses of $8,460,000 and $1,537,000 for the three and
six months ended March 31, 2000, respectively. The net loss for the six months
ended March 31, 2000 resulted from the net effect of recognizing a $9,751,000
gain on the sale of IRL in December 1999, offset by operating expenses for the
six months of $4,877,000 and the expensing of $6,664,000 for purchased
in-process research and development in March 2000. We had net losses of
$6,176,000 and $12,297,000 for the three and six months ended March 31, 1999,
respectively.
We did not have any revenue during the three months ended March 31,
2000. Contract and license fee revenue was $100,000 and $400,000 for the six
months ended March 31, 2000 and 1999, respectively. All of this revenue resulted
from an IRL collaboration with Merck & Co., Inc. We will not receive any
additional revenue from this collaboration, because it was sold with the other
IRL assets.
Our research and development ("R&D") expenses decreased $4,356,000
(78%) to $1,246,000 for the for the three months ended March 31, 2000 from
$5,602,000 for the three months ended March 31, 1999. R&D expenses decreased
$7,795,000 (68%) to $3,625,000 for the six months ended March 31, 2000 from
$11,420,000 for the six months ended March 31, 1999. The lower expenses were
primarily due to the result of discontinuing our bucindolol development program
in the fourth quarter of fiscal 1999 and to the sale of our IRL operation in
December 1999.
During the last quarter of fiscal 1999, we discontinued our bucindolol
development program and, therefore, we did not incur any bucindolol related
expenses this fiscal year. During the six months ended March 31, 1999, we
incurred $4,073,000 of bucindolol related R&D expenses. We do not anticipate any
additional expenses for bucindolol.
Because we sold IRL at the end of December 1999, we did not incur any
significant R&D expenses for IRL during the three months ended March 31, 2000.
R&D expenses for IRL were $1,376,000 for the three months ended December 31,
1999 and for the six months ended March 31, 2000, respectively. IRL expenses
were $2,143,000 and $4,615,000 for the three and six months ended March 31,
1999, respectively. We do not expect any additional expense for IRL in the
future.
We incurred $461,000 and $733,000 of R&D expenses for OP2000 during the
three months and six months ended March 31, 2000, respectively. OP2000 expenses
were $44,000 and $80,000 for the three months and six months ended March 31,
1999, respectively. The higher expenses in fiscal 2000 were primarily due to
costs incurred in connection with our Phase 1 clinical trials that began in
October 1999.
10
R&D expenses for our liver cell program increased $123,000 (82%) to
$273,000 for the three months ended March 31, 2000 from $150,000 for the three
months ended March 31, 1999. These R&D expenses increased $164,000 (50%) to
$493,000 for the six months ended March 31, 2000 from $329,000 for the six
months ended March 31, 1999. The higher expenses in the current fiscal year
resulted primarily from higher patent fees and expenses and more R&D staff time
being devoted to the program.
R&D expenses for our antioxidant program decreased $359,000 (54%) to
$309,000 for the three months ended March 31, 2000 from $668,000 for the three
months ended March 31, 1999. These R&D expenses decreased $670,000 (54%) to
$574,000 for the six months ended March 31, 2000 from $1,244,000 for the six
months ended March 31, 1999. The decrease in expenses from fiscal 1999 to fiscal
2000 was primarily due to the reduction of outside contract services and
sponsored research costs.
General and administrative ("G&A") expenses decreased $152,000 (18%) to
$690,000 for the three months ended March 31, 2000 from $842,000 for the three
months ended March 31, 1999. G&A expenses decreased $237,000 (16%) to $1,252,000
for the six months ended March 31, 2000 from $1,489,000 for the six months ended
March 31, 1999. The higher G&A expenses in fiscal 1999 were primarily for
expenses related to the bucindolol program, which was terminated in the last
quarter of fiscal 1999.
In May 1998, we acquired Transcell Technologies, Inc., which became
IRL. We issued the third and final installment of the purchase price of 856,861
shares of Incara common stock to the former stockholders of Transcell on
February 8, 2000. The number of shares issued was calculated using a formula
based on the market price of Incara common stock prior to the stock issuance
date. The issuance of these additional shares did not impact our fiscal 2000
operating results, because the value of these shares was included in the
determination of the purchase price of Transcell in fiscal 1998.
For the three months and six months ended March 31, 2000, we recognized an
in-process research and development charge of $6,664,000 as a result of the
acquisition of the minority interests of Renaissance and Aeolus. We allocated
the total purchase price to in-process research and development because it had
not reached feasibility and it had no alternative future use at the date of
acquisition. Renaissance and Aeolus have spent approximately $10,000,000 through
March 31, 2000 and estimate that in excess of $50,000,000 over at least the next
five years will be spent to complete the research and development. The cost to
complete a portion of this research and development may be shared with a
collaborative partner in the future.
Liquidity and Capital Resources
At March 31, 2000, we had cash and cash equivalents and marketable
securities of $10,522,000, an increase of $5,562,000 from September 30, 1999.
Cash increased due to the receipt of $11,000,000 from the sale of IRL, offset by
operating costs for the six months. We believe we have adequate financial
resources to fund our current operations at least into calendar 2001.
11
We expect to incur substantial additional costs and losses over the
next few years. Our cash requirements for subsequent periods will depend on
numerous factors, particularly the progress of our research and development
programs. Significant additional funds will be required for us to continue our
clinical program evaluating the use of OP2000 and to complete preclinical
activities and begin clinical trials for our liver precursor cell and
antioxidant programs.
We have completed two Phase 1 clinical trials for OP2000, the most
recent having been completed in April 2000. These trials looked at single and
multiple dose administrations of the drug, and preliminary results indicate that
we will be able to give OP2000 on a once a day basis. We plan to begin a Phase
2/3 safety and efficacy trial in ulcerative colitis patients in the fall of
2000. We have an exclusive license from Opocrin, in all countries other than
Japan and Korea, for an issued patent claiming certain oligosaccharides derived
from heparin and their use in antiatherosclerotic activity to develop and
commercialize OP2000. We are aware of a recently issued patent claiming the use
of certain fractions of heparin for the treatment of inflammatory bowel disease.
We do not believe OP2000 falls within the scope of this patent. If OP2000 were
to be determined to fall within the scope of this patent and if the patent's
claims were found to be valid, we would have to license this patent in order to
commercialize OP2000. If this were the case, we might not be able to license
this patent at a reasonable cost, which would result in our not being able to
market OP2000.
Incara is exploring two patient populations for the initial clinical
trials of liver precursor cell transplantation. The first group consists of
infants with life-threatening inborn errors of metabolism who are too young for
liver transplants. This patient population represents a group with limited
alternatives where improvement in patient condition and production of the
missing gene products would demonstrate the function of the transplanted cells.
The second series of clinical trials being planned involves adults with such
severe cirrhosis and other forms of chronic liver failure that they could become
candidates for a transplant. Incara targets these initial clinical trials to
begin in the first half of 2001.
In a model of ischemic stroke, where the middle cerebral artery of a
rat is blocked for 90 minutes and then unblocked, our lead antioxidant compound
reduced infarct size significantly when introduced as late as 7 1/2 hours after
the start of the stroke. Stroke is a form of ischemia/reperfusion injury, and
this compound is also highly active in a model of liver ischemia/reperfusion
injury. We are currently dual-tracking another antioxidant compound and we
anticipate selecting the most promising drug candidate for stroke by the fall of
2000, once more data is available. Assuming satisfactory completion of the
preclinical studies, we intend to initiate Phase 1 clinical trials for an
antioxidant compound in mid 2001.
We might acquire other products, technologies or businesses that
complement our existing or planned products or programs, although we currently
have no understanding, commitment or agreement with respect to any such
acquisitions.
We intend to seek additional capital necessary to execute our business
plan through one or more potential sources, including the sale of common or
preferred stock in private equity
12
offerings and from new collaborations related to one or more of our product
development programs. Adequate funds might not be available at all or on terms
acceptable or favorable to us. It is currently difficult for biotechnology
companies to raise funds in the equity markets. Any additional equity financing,
if available, would likely result in substantial dilution to Incara's
stockholders. If we are successful in obtaining collaborations for any of our
programs, we expect to relinquish rights to technologies, product candidates or
markets which we might otherwise develop ourselves. If we are unable to enter
into new collaborations or raise additional capital to support our current level
of operations, we might be required to scale back, delay or discontinue one or
more of our research and development programs, or obtain funds on terms that are
not favorable to us, which could have a material adverse affect on our business.
Reduction or discontinuation of research and development programs could result
in additional charges, which would be reflected in the period of the reduction
or discontinuation.
On January 18, 2000, our Board of Directors authorized the repurchase
of up to $2,000,000 of our common stock during the following two months through
purchases on the stock market. During this period, we repurchased 104,100 shares
of our common stock at a cost of $332,000.
13
Item 6. Exhibits and Reports on Form 8-K.
--------------------------------
(a) Exhibits
2.7 Agreement and Plan of Merger dated as of March 24, 2000, by and among Incara Pharmaceuticals
Corporation, Aeolus Acquisition Corporation and Aeolus Pharmaceuticals, Inc.
2.8 Agreement and Plan of Merger dated as of March 24, 2000, by and among Incara Pharmaceuticals
Corporation, RCT Acquisition Corporation and Renaissance Cell Technologies, Inc.
10.8 Incara Pharmaceuticals Corporation 1994 Stock Option Plan, as amended
10.49* License Agreement dated August 23, 1999 between The University of North Carolina at Chapel
Hill and Renaissance Cell Technologies, Inc.
10.50* License Agreement, effective July 1996, between Albert Einstein College of Medicine of
Yeshiva University and Renaissance Cell Technologies, Inc.
27 Financial Data Schedule, which is submitted electronically to the Securities and Exchange
Commission for information only and not filed.
* Confidential treatment requested.
(b) The following report on Form 8-K was filed by the Company during the six
months ended March 31, 2000.
Date Filed Event
October 11, 1999 Issuances under 1999 Equity Incentive Plan
14
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INCARA PHARMACEUTICALS CORPORATION
Date: May 12, 2000 By: /s/ Richard W. Reichow
---------------------------------------------
Richard W. Reichow, Executive Vice President,
Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
15